Smokers…. And 💉👻’s
ungVax is an experimental, first-of-its-kind vaccine designed to prevent non-small cell lung cancer (NSCLC) by training the immune system to detect and destroy abnormal lung cells before they become cancerous. Using technology similar to the Oxford/AstraZeneca COVID-19 vaccine, it delivers genetic instructions to help the immune system recognize "red flag" neoantigens on early-stage pre-cancerous cells.
Cancer Research UK - Cancer News
Cancer Research UK - Cancer News
+3
Key Details About LungVax:
Target Population: High-risk individuals, particularly smokers or former smokers aged 55–74, who are most susceptible to developing lung cancer.
Technology: It uses a viral vector (ChAdOx2) to introduce DNA into the body, encouraging a targeted T-cell response against cancer-related proteins.
Development Stage: Developed by researchers at the University of Oxford, UCL, and the Francis Crick Institute with funding from Cancer Research UK and the CRIS Cancer Foundation.
Trial Timeline: A Phase I trial is planned to start in summer 2026, focusing on safety and immune response in around 40 participants.
Purpose: The goal is to act as a preventative measure for those at high risk, though it is not a replacement for quitting smoking.
University of Oxford
University of Oxford
+5
The project, led by Professor Sarah Blagden and Professor Mariam Jamal-Hanjani, aims to target lung cancer at its earliest stage to improve the currently low survival rates for the disease
|
Smokers…. And 💉👻’s...[more]